Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • Flights
  • More
    • Travel
    • Hotels
    • Real Estate
    • My Bing
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Sent to ER for misbehavior
Subpoena request denied
Dad has leg amputated
Mauritania's ex-pres jailed
Ericsson shares jump
‘I couldn’t actually walk’
Charged Lemonade 2nd suit
Charged with raping student
Jaguars' Lawrence injured
Virginia house explosion
'Hell's Kitchen' musical
Earthquake hits Hawaii
UK unveils strict visa norms
Arrested during traffic stop
Branson's investment halt
Lawsuit against Fontana
Choate hired as head coach
Tacoma officer testifies
14 killed in Thai bus crash
'GTA VI' trailer
Cyclone Michaung hits India
Data breach affects 6.9M
COP28 climate talks
To visit Saudi Arabia, UAE
2024 free days park visits
Jackpot hits $435 million
American math scores fall
Cannes Film Market 2024
Historic fifth straight win
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
5,210 results
Proactiveinvestors26d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
1don MSN
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) ...
The Motley Fool18d
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...
Reuters21d
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial
Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...
Hosted on MSN26d
AstraZeneca CEO Pascal Soriot: Treatment of cancer in the last few years has been 'remarkable'
AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...
Proactiveinvestors26d
AstraZeneca investors could "take some reassurance” from obesity drug bet
AstraZeneca PLC (LSE:AZN) had a mixed day of news, with the bright spots of a foray into anti-obesity drugs and an upgrade to its full-year outlook somewhat clouded by news about potential lawsuits ...
MarketWatch26d
AstraZeneca Shares Rise After Guidance Increase
Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...
Investing15d
AstraZeneca: Leading bank tells us why the stock is a core holding
Proactive Investors - Barclays (LON:BARC) Capital has issued an optimistic assessment of AstraZeneca PLC (LON:AZN)'s shares, recommending an 'overweight' position with a target price of £135, a ...
Morningstar1d
AstraZeneca PLC ADR AZN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Proactive Investors26d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Get the Bing App
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices